Filtered By:
Specialty: Cardiology
Drug: Pradaxa
This page shows you your search results in order of relevance. This is page number 3.
Order by Relevance | Date
Total 478 results found since Jan 2013.
Stroke Prevention with Oral Anticoagulants: Summary of the Evidence and Efficacy Measures as an Aid to Treatment Choices
AbstractAtrial fibrillation (AF) is an established risk factor for a first or recurrent stroke. Despite proven efficacy in preventing stroke in patients with AF, warfarin is underused, partly due to safety concerns. Recent randomized trials have shown that non-vitamin K antagonist oral anticoagulants (NOACs) such as dabigatran (a direct thrombin inhibitor) and apixaban, edoxaban, and rivaroxaban (factor Xa inhibitors) are not only non-inferior or superior to warfarin but also demonstrate a decreased risk of cerebrovascular bleeding among patients with AF and moderate to high risk of stroke. Additionally, NOACs have an adva...
Source: Cardiology and Therapy - June 1, 2018 Category: Cardiology Source Type: research
Individual Treatment Effect Estimation of 2 Doses of Dabigatran on Stroke and Major Bleeding in Atrial Fibrillation: Results from the RE-LY Trial.
CONCLUSIONS: The absolute treatment benefits and harms of dabigatran in atrial fibrillation can be estimated based on readily available patient characteristics. Such treatment effect estimations can be used for shared decision-making before starting dabigatran treatment, and to determine the optimal dose.
CLINICAL TRIAL REGISTRATION: URL: https://clinicaltrials.gov Unique identifier: NCT00262600.
PMID: 31046423 [PubMed - as supplied by publisher]
Source: Circulation - May 2, 2019 Category: Cardiology Authors: Stam-Slob MC, Connolly SJ, van der Graaf Y, van der Leeuw J, Dorresteijn JAN, Eikelboom JW, Peters RJG, Alings M, Visseren FLJ Tags: Circulation Source Type: research
Practical Considerations in the Use of Novel Oral Anticoagulants for Stroke Prevention in Nonvalvular Atrial Fibrillation
This article is protected by copyright. All rights reserved.
Source: Cardiovascular Therapeutics - October 1, 2013 Category: Cardiology Authors: Steven Deitelzweig Tags: Unsolicited Review Source Type: research
Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: A French payer perspective.
CONCLUSION: This study suggests that the use of dabigatran in French atrial fibrillation patients is cost-effective, according to usually accepted thresholds.
PMID: 24973113 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - June 24, 2014 Category: Cardiology Authors: Chevalier J, Delaitre O, Hammès F, de Pouvourville G Tags: Arch Cardiovasc Dis Source Type: research
The budget impact of left atrial appendage closure compared with adjusted-dose warfarin and dabigatran etexilate for stroke prevention in atrial fibrillation
Conclusion
The majority of LAAC costs are borne in the first year, while costs for pharmaceutical strategies continue to accrue year on year. Thus, LAAC represents an opportunity for savings to healthcare systems in the long term. This is an important consideration for payers in evaluating lifetime treatment strategies in AF.
Source: Europace - July 29, 2014 Category: Cardiology Authors: Amorosi, S. L., Armstrong, S., Da Deppo, L., Garfield, S., Stein, K. Tags: Atrial fibrillation Source Type: research
Stroke prevention in atrial fibrillation: evidence from real-life studies
Atrial fibrillation (AF) is an increasing public health issue, especially owing to an accompanying five-fold increased risk of stroke. Anticoagulants are the cornerstone of therapy for stroke prevention in AF. The clinical benefits of vitamin K antagonists (VKAs; namely warfarin) shown in randomized controlled trials (RCTs) have been challenged when used in clinical practice by issues including the need for international normalized ratio (INR) monitoring, food and drug interactions, low time in the therapeutic range in substantial numbers of patients, and serious bleeding events. Combined, these have led to both an under-i...
Source: European Journal of Heart Failure Supplements - July 10, 2015 Category: Cardiology Authors: Akao, M., Beyer-Westendorf, J., Goto, S., Peterson, E. Tags: Articles Source Type: research
Design and rationale of dabigatran's stroke prevention in real life in Turkey (D-SPIRIT).
CONCLUSION: Potential results of D-SPIRIT registry will add data from clinical practice to those from the RE-LY trial to expand knowledge of dabigatran etexilate treatment in patients with NVAF.
PMID: 27138311 [PubMed - in process]
Source: Turk Kardiyoloji Dernegi arsivi - March 31, 2016 Category: Cardiology Authors: Türk UÖ, Alioğlu E, Tunçer E, Özpelit ME, Pekel N, Tengiz İ, Çetin N, Dalgıç O, Topaloğlu C, Bilgin N, Altın C, Özdemirkıran T, Tülüce K, Türkoğlu Eİ, Özpelit E Tags: Turk Kardiyol Dern Ars Source Type: research
Non-Vitamin K Antagonist Oral Anticoagulants and Antiplatelet Therapy for Stroke Prevention in Patients With Atrial Fibrillation: A Meta-Analysis of Randomized Controlled Trials
Non-vitamin K antagonist oral anticoagulants (NOACs) are frequently used to prevent stroke in patients with atrial fibrillation. These patients are often also on aspirin or other antiplatelet agents. It is possible that treatment with both NOACs and aspirin or other antiplatelet drug may be effective in decreasing stroke, but data are sparse regarding the efficacy and safety of using both agents for stroke prevention. To address these issues, data were pooled from the 4 recent randomized, controlled trials of NOACs: apixaban, rivaroxaban, dabigatran, and edoxaban, which included 42,411 patients; 14,148 (33.4%) were also on...
Source: Cardiology in Review - August 9, 2016 Category: Cardiology Tags: Review Articles Source Type: research
Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios
Publication date: September 2018Source: IJC Heart & Vasculature, Volume 20Author(s): Ting-Yung Chang, Jo-Nan Liao, Tze-Fan Chao, Jennifer Jeanne Vicera, Chin-Yu Lin, Ta-Chuan Tuan, Yenn-Jiang Lin, Shih-Lin Chang, Li-Wei Lo, Yu-Feng Hu, Fa-Po Chung, Shih-Ann ChenAbstractAtrial fibrillation (AF) has become the most prevalent arrhythmia and it will increase the risk of ischemic stroke, heart failure, mortality, sudden cardiac death, myocardial infarction, and dementia. Stroke prevention with oral anticoagulant is crucial for management of AF patients. Vitamin K antagonist, which inhibits the clotting factors II, VII, IX and X...
Source: IJC Heart and Vasculature - September 1, 2018 Category: Cardiology Source Type: research
Non-Vitamin K Antagonist Oral Anticoagulants in Secondary Stroke Prevention in Atrial Fibrillation Patients: An Updated Analysis by Adding Observational Studies
ConclusionBased on current data, the use of NOACs is at least non-inferior to the use of VKAs in AF patients for secondary stroke prevention irrespective of NOAC type.
Source: Cardiovascular Drugs and Therapy - April 14, 2020 Category: Cardiology Source Type: research
Anticoagulants for Stroke Prevention in Atrial Fibrillation in Elderly Patients
AbstractIschaemic stroke and systemic embolism are the major potentially preventable complications of atrial fibrillation (AF) leading to severe morbidity and mortality. Anticoagulation using vitamin K antagonists (VKA) or non-vitamin K oral anticoagulants (NOACs) is mandatory for stroke prevention in AF. Following approval of the four NOACs dabigatran, rivaroxaban, apixaban, and edoxaban, the use of VKA is declining steadily. Increasing age with thresholds of 65 and 75 years is a strong risk factor when determining annual stroke risk in AF patients. Current recommendations such as the “2016 Guidelines for the manageme...
Source: Cardiovascular Drugs and Therapy - April 28, 2020 Category: Cardiology Source Type: research
Predictors of Development of Atrial Fibrillation in Patients With Embolic Stroke Of Undetermined Source: An Analysis of the RE-SPECT ESUS Trial
Conclusions: Besides age as the most important variable, several other factors, including hypertension, higher body mass index, and lack of diabetes, are independent predictors of AF after ESUS. When baseline NT-proBNP was available, only older age and elevation of this biomarker were predictive of subsequent AF. Understanding who is at higher risk of developing AF will assist in identifying patients who may benefit from more intense, long-term cardiac monitoring.PMID:34649459 | DOI:10.1161/CIRCULATIONAHA.121.055176
Source: Circulation - October 15, 2021 Category: Cardiology Authors: Maria Cecilia Bahit Ralph L Sacco J Donald Easton Juliane Meyerhoff Lisa Cronin Eva Kleine Claudia Grauer Martina Brueckmann Hans-Christoph Diener Renato D Lopes Michael Brainin Philippe Lyrer Rolf Wachter Tomas Segura Christopher B Granger Source Type: research
Dabigatran for stroke prevention in real life in a sample of population from Turkey: D-SPIRIT registry
CONCLUSION: This registry obtained an important overview of the current safety and effectiveness of the dabigatran etexilate in Turkey. Our results indicate similar rates of thromboembolic and bleeding events with pivotal phase 3 trial and other real-life registries. However, rate of undertreatment usage of dabigatran etexilate in real life was found to be considerable.PMID:34881702 | DOI:10.5543/tkda.2021.07734
Source: Turk Kardiyoloji Dernegi arsivi - December 9, 2021 Category: Cardiology Authors: Cihan Alt ın Caner Topalo ğlu Nurullah Çetin Onur Dalg ıç Veysel Yavuz Emin Alio ğlu Nazile Bilgin Cenk Ekmek çi Nihat Pekel Mehmet Emre Özpelit E şref Tunçer Ebru İpek Türkoğlu Kamil T ülüce Umut Kocaba ş K ıvanç Yüksel U ğur Önsel T Source Type: research
